Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE MEASUREMENTS (Tables)

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2021

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS

	As of September 30, 2021				Fair Value Measurements
	Carrying		Fair		As of September 30, 2021
	Amount		Value		Level 1		Level 2		Level 3
					(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,136	$	2,136	$	-	$	-	$	2,136
Other long-term liabilities:
Warrant liability ⁽²⁾		158		158		-		-		158
	$	2,294	$	2,294	$	-	$	-	$	2,294

	As of December 31, 2020				Fair Value Measurements
	Carrying		Fair		As of December 31, 2020
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,216	$	2,216	$	-	$	-	$	2,216
Other long-term liabilities:
Warrant liability ⁽²⁾		21		21		-		-		21
	$	2,237	$	2,237	$	-	$	-	$	2,237

⁽¹⁾⁽²⁾See Note 9, Accrued Expenses and Long-Term Liabilities

(1)	See Note 9, Accrued Expenses and Long-Term Liabilities
(2)	See Note 9, Accrued Expenses and Long-Term Liabilities

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION

A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to September 30, 2021 is as follows:

								Cancellation of Obligation/		Adjustment to Fair Value/
	December 31, 2020		Payments			Accretion		Conversions Exercises		Mark to Market			September 30, 2021
	(unaudited)
Contingent consideration liability	$	2,216	$	(398	)	$	375	$	-	$	(57	)	$	2,136

Underwriters Warrants		21		-			-		-		137			158
	$	2,237	$	(398	)	$	375	$	-	$	80		$	2,294